Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08SPH
|
|||
| Drug Name |
Eculizumab
|
|||
| Synonyms |
Eculizumab (intravitreal, AMD); Eculizumab (intravitreal, AMD), Alexion; Eculizumab (intravitreal, age-related macular degeneration), Alexion
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Neuromyelitis optica [ICD-11: 8A43; ICD-10: G36.0; ICD-9: 341] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Alexion Pharmaceuticals Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN complement C5 protein (C5) | Target Info | Inhibitor | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | ClinicalTrials.gov (NCT04346797) CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort | |||
| REF 3 | Complement as a target in COVID-19 Nat Rev Immunol. 2020 Apr 23. | |||
| REF 4 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 125166. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.